Chemomab Therapeutics Ltd expected to post a loss of 4 cents a share - Earnings Preview

Chemomab Therapeutics

15/03/2023 11:01

* Chemomab Therapeutics Ltd  CMMB.OQ   CMMB.O  is expected
to show
no change in quarterly revenue when it reports  results on March
17 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Chemomab
Therapeutics Ltd
is for a loss of 4 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Chemomab
Therapeutics Ltd is $12​, above​ its last closing price
of $1.49. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.64       -0.33      -0.03     Beat    89.4
 Jun. 30 2022              -0.25      -0.54     Missed  -111.8
 Mar. 31 2022  -0.47       -0.24      -0.44     Missed  -79.6​
 Dec. 31 2021  -0.16       -0.10      -0.44     Missed  -325.8
 ​​Sep.                    -0.14      -0.26     Missed  -79.3
 30 2021                                                
 Jun. 30 2021  -0.10       -0.11      -0.26     Missed  -126.1
                                                        ​
 Mar. 31 2021  -0.43       -0.43      -0.22     Beat    48.8
 This summary was machine generated March 15 at 11:01 GMT.  All
figures in US dollars  unless otherwise stated